Obstructive findings in sarcoidosis, diagnosis and therapies modalities
Jelica Videnović-Ivanov, Snežana Filipović, Violeta Vučinić, Vlada Zugic
Abstract
Jelica Videnović-Ivanov, Snežana Filipović, Violeta Vučinić, Vlada Zugic
Abstract
Introduction: Symptoms of respiratory disturbances are common during the course of sarcoidosis. The aim of analysis is to notifie obstructive findings in sarcoidosis. Method: The analyses is restrospective in all incominig patients to the Clinic for lung diseases and tuberculosis CC of Serbia in Belgrade. Results: 127 (8,7%) patients with dry cough and occasionaly dyspnea had the impairent of lung function. The main findings were: FEVl / VC 63,1% in 57- 44,8% patients; in 27-21,1% patients – FEVl / FVC were 55,7% , in 3-2,3% patients FEVl / FVC were 68.7 %. Gender distribution were as followed: 264 (66,2%)Female- Male 135 (33,8%); average ages were 43,32 years. Extrathoracis sarcoidosis involvement were find out in 3 (2.3%) patients (skin, lymph nodes,).Lung and nonpulmonary sarcoidosis is notify in 27 pts and in 97 pts lung were the only sarcoidosis manifestation. Radiographic stadium of lung involvement: I-87(68.5%), II-31(24,4%), III-7%(5,%), IV-1 (0,78%). Acute onset of sarcoidosis is predominatly with average level of ACE: 75.3 U / L. After obtaining the diagnosis of sarcoidosis, inhaled corticosteroides were administered, 160 mcg-daily through 3 months with controls which meansa :ACE and UCa/24h levels, lung function, chest X ray. Regression of symptoms such as dry cough were obtained in 55% patients after the period of 2 months; 45% patients were excluded due to persistence of symptoms seeking prednisone. Conclusion – inhaled corticosteroid have the role in sarcoidosis treatment resolving symptoms such as cough, improvement of FEV1, but the main therapy in most of the patients is still orally administired prednisone.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Introduction: Symptoms of respiratory disturbances are common during the course of sarcoidosis. The aim of analysis is to notifie obstructive findings in sarcoidosis. Method: The analyses is restrospective in all incominig patients to the Clinic for lung diseases and tuberculosis CC of Serbia in Belgrade. Results: 127 (8,7%) patients with dry cough and occasionaly dyspnea had the impairent of lung function. The main findings were: FEVl / VC 63,1% in 57- 44,8% patients; in 27-21,1% patients – FEVl / FVC were 55,7% , in 3-2,3% patients FEVl / FVC were 68.7 %. Gender distribution were as followed: 264 (66,2%)Female- Male 135 (33,8%); average ages were 43,32 years. Extrathoracis sarcoidosis involvement were find out in 3 (2.3%) patients (skin, lymph nodes,).Lung and nonpulmonary sarcoidosis is notify in 27 pts and in 97 pts lung were the only sarcoidosis manifestation. Radiographic stadium of lung involvement: I-87(68.5%), II-31(24,4%), III-7%(5,%), IV-1 (0,78%). Acute onset of sarcoidosis is predominatly with average level of ACE: 75.3 U / L. After obtaining the diagnosis of sarcoidosis, inhaled corticosteroides were administered, 160 mcg-daily through 3 months with controls which meansa :ACE and UCa/24h levels, lung function, chest X ray. Regression of symptoms such as dry cough were obtained in 55% patients after the period of 2 months; 45% patients were excluded due to persistence of symptoms seeking prednisone. Conclusion – inhaled corticosteroid have the role in sarcoidosis treatment resolving symptoms such as cough, improvement of FEV1, but the main therapy in most of the patients is still orally administired prednisone.
Key concepts: Medicine, Sarcoidosis, Prednisone, Internal medicine, Lung, Pulmonary function testing, Dermatology